Shanghai Handu Pharmaceutical Technology Co., Limited announced that it will receive CNY 127,400,000 in an equity round of funding on March 25, 2021. The transaction will include participation from new investors, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (SEHK:1349) for CNY 102,420,000 and Shanghai Jinpu Health Phase III Equity Investment Fund Partnership Enterprise (Limited Partnership) for CNY 24,980,000 for 9.6503% stake to subscribe to new registered capital. The transaction has been approved at the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (SEHK:1349)'s 6th meeting of the 7th directorate and does not need the shareholders’ approval.